Abstract
Previous studies have shown that mRNA COVID-19 vaccines are highly effective at preventing SAR-CoV-2 infection by generating an immune response, which in part produces SARS-CoV-2 IgG antibodies in serum. In this study, we hypothesized that COVID-19 vaccines may elicit production of SARS-CoV-2 IgG antibodies in the upper respiratory tract, such as in oral and nasal mucosal fluid. To test that hypothesis, we enrolled 114 participants within 3-7 days of receiving the first dose of the Moderna mRNA COVID-19 vaccine and collected oral mucosal fluid samples on days 5, 10, 15, and 20 after each vaccine dose. Of participants naive to SARS-CoV-2 (n = 89), 79 (85.4%) tested positive for SARS-CoV-2 IgG antibodies by time point 2 (10 days +/-2 days after first vaccine dose), and 100% tested positive for SARS-CoV-2 IgG by time point 3 (15 days +/-2 days after first vaccine dose). Additionally, we collected paired oral mucosal fluid and anterior nares samples from 10 participants who had received both vaccine doses. We found that participants had an average SARS-CoV-2 IgG antibody concentration of 2496.0 +/-2698.0ng/mL in nasal mucosal fluid versus 153.4 +/-141.0ng/mL in oral mucosal fluid. Here, we demonstrate detection and longitudinal persistence of SARS-CoV-2 IgG antibodies in upper respiratory tract specimens following COVID-19 mRNA vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Curative Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols were approved by the Advarra Institutional Review Board (IRB# Pro00048737 and Pro00045766).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request from Corresponding Author
Keywords
- OSCD
- OraSure® Technologies Oral Specimen Collection Device
- rRT-PCR
- Real-time reverse transcription polymerase chain reaction
- ELISA
- Enzyme-Linked Immunosorbent Assay
- COVID-19
- 2019 novel coronavirus
- RNA
- ribonucleic acid
- mRNA
- Messenger ribonucleic acid
- IgA
- Immunoglobulin A
- IgG
- Immunoglobulin G
- IgM
- Immunoglobulin M
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- LOD
- Limit of Detection
- LOQ
- Limit of Quantification
